KPV Manufacturer 99% Purity Bulk KPV CAS Number 67727-97-3 Peptide lyophilized powder, 5mg/bottle, 10 bottles/box,

KPV, also known as α‑MSH (11‑13), is a synthetic short‑chain tripeptide composed of L‑lysine, L‑proline and L‑valine, with the amino‑acid sequence Lys‑Pro‑Val. Its CAS number is 67727‑97‑3, molecular formula C₁₆H₃₀N₄O₄ and molecular weight 342.43 g/mol. Derived from the C‑terminal fragment of α‑melanocyte‑stimulating hormone (α‑MSH), KPV retains the prominent anti‑inflammatory properties of the parent molecule, while eliminating melanogenic pigment‑inducing activity, which makes it a highly valuable bioactive peptide for laboratory research, cosmetic raw‑material development and pre‑clinical pharmacological exploration. KPV is mainly supplied as lyophilized white‑to‑off‑white powder, with typical HPLC purity reaching 98%‑99%, available in bulk powder and via packaging for global buyers from research institutes, cosmetic enterprises and biotech laboratories.
Chemically, KPV is a small‑molecule linear peptide. Its compact molecular structure brings outstanding tissue‑penetration performance. Different from full‑length α‑MSH, KPV does not trigger skin‑darkening responses related to melanocortin receptor activation, so researchers can focus on its immunomodulation and anti‑inflammatory effects without pigment‑change interference. As a synthetic bio‑peptide product, KPV raw material adopts strict peptide‑synthesis and purification procedures. Finished lyophilized powder shows good physical‑chemical stability under proper preservation conditions. Long‑term storage requires sealed environment at ‑20℃ away from light and moisture, with shelf life up to 3 years; short‑term preservation can be performed at 2‑8℃, and reconstituted aqueous solution needs low‑temperature storage to avoid peptide degradation caused by high temperature and microbial contamination. It should be emphasized that KPV is for research‑use only (RUO). It is not approved as pharmaceutical drug, dietary supplement or edible ingredient.
The core biological value of KPV lies in its multi‑target anti‑inflammatory and immune‑regulating mechanisms. A large number of in‑vitro cell experiments and animal‑model researches indicate that KPV can suppress the NF‑κB signaling pathway, which is the core regulatory pathway of inflammatory reaction, and further down‑regulate the secretion of multiple pro‑inflammatory cytokines including TNF‑α, IL‑1β, IL‑6 and IL‑8. KPV can be absorbed by intestinal epithelial cells through peptide transporter PepT1, and produce anti‑inflammatory effects inside cells, restraining over‑activated immune response and reducing tissue damage induced by excessive inflammation. Unlike broad‑spectrum immunosuppressive substances, KPV conducts immune homeostasis regulation instead of completely suppressing immune system, which provides research foundation for developing low‑irritation anti‑inflammatory candidate substances. In pre‑clinical animal models of inflammatory bowel disease, orally administered KPV effectively relieved colitis symptoms, reduced colon tissue infiltration of inflammatory cells, lowered pathological injury scores and promoted the repair of intestinal mucosal barrier. Besides intestinal‑inflammation related studies, KPV also shows research potential in skin‑inflammation fields. In keratinocyte and skin‑tissue related tests, KPV relieves local inflammatory response, assists skin barrier recovery, and exhibits mild antibacterial activity against partial pathogenic bacteria such as Staphylococcus aureus and Candida albicans, bringing new exploration directions for wound‑repair and soothing‑cosmetic raw‑material research.
In terms of application scenarios, KPV raw material supplied on ECHEMI mainly serves three major fields. First is academic and pharmaceutical laboratory research. Global research institutions purchase KPV lyophilized powder to carry out mechanism research on inflammatory diseases, explore its intervention effect on intestinal inflammation, skin inflammation and other chronic inflammatory states, and explore new therapeutic molecule candidates. All relevant experiments must be implemented in laboratory environment, following standardized research‑operation specifications. Second is cosmetic raw‑material development. R&D teams apply KPV in formula exploration of soothing, repairing cosmetics. Relying on its pre‑clinical anti‑inflammatory and barrier‑repair related research background, developers study its topical application potential for sensitive‑skin care, inflammatory‑skin soothing and wound auxiliary repair. It is noteworthy that cosmetic application still stays in formula‑exploration stage, and finished products need to pass regulatory local compliance assessment before market launch. Third is biotech‑product development. Combined with nanoparticle delivery system and other formulation technologies, researchers study optimized delivery schemes of KPV, to improve its bioavail